A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.

A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.

Item
http://www.wikidata.org/entity/Q34615116
Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatmentA phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoNF-κB as potential target in the treatment of melanoma.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.Metastatic melanoma - a review of current and future drugsSystemic therapy of non-resectable metastatic melanoma.Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.Virus reactivation: a panoramic view in human infectionsMALT1 promotes melanoma progression through JNK/c-Jun signalingMyeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
P2860

A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.

Item
http://www.wikidata.org/entity/Q34615116
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I trial of bortezomib ...... lation of therapeutic targets.
@ast
A phase I trial of bortezomib ...... lation of therapeutic targets.
@en
A phase I trial of bortezomib ...... lation of therapeutic targets.
@nl
type
label
A phase I trial of bortezomib ...... lation of therapeutic targets.
@ast
A phase I trial of bortezomib ...... lation of therapeutic targets.
@en
A phase I trial of bortezomib ...... lation of therapeutic targets.
@nl
prefLabel
A phase I trial of bortezomib ...... lation of therapeutic targets.
@ast
A phase I trial of bortezomib ...... lation of therapeutic targets.
@en
A phase I trial of bortezomib ...... lation of therapeutic targets.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
A phase I trial of bortezomib ...... lation of therapeutic targets.
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-09-2087
P407
P433
P478
P50
P577
P5875
P698
P921
P932